undamentalytics Newsletter
Sign in

Septerna, Inc. revenue

Septerna, Inc.'s revenue was $46.0m in fiscal 2025, up 4174.5% on the year before. Over the last twelve months it was $98.9m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue014699
Growth on the year before—+611.9%+>999%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Septerna, Inc. $98.9m 13520.1% —
Agios Pharmaceuticals, Inc. $98.3m 140.6% 69.6%
Kymera Therapeutics, Inc. $102m 133.8% 29.7%
Xencor Inc $105m -28.6% -2.5%
4d Molecular Therapeutics, Inc. $92.0m 278712.1% 242.8%
Verastem, Inc. $87.5m 26.4% 58.4%

Compare with peers

Head to head: AGIO vs SEPNKYMR vs SEPNSEPN vs XNCRFDMT vs SEPN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Septerna, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Septerna, Inc.